Molecular mechanisms of T cell co-stimulation and co-inhibition
Tóm tắt
Từ khóa
Tài liệu tham khảo
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T. & Thompson, C. B. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7, 4472–4481 (1987). This paper identified CD28 as a co-stimulator that could amplify TCR signalling to induce proliferation and IL-2 production.
Bretscher, P. & Cohn, M. A theory of self-nonself discrimination. Science 169, 1042–1049 (1970). In this paper Bretscher and Cohn first proposed a model in which two signals would be required for cellular activation of B cells as a mechanism of self–non-self discrimination.
Mueller, D. L., Jenkins, M. K. & Schwartz, R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445–480 (1989). This paper showed that TCR signalling in the absence of additional signals was insufficient to activate T cells and rendered T cells unresponsive to subsequent stimulation.
Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K. & Escors, D. Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy. Immunol. Endocr. Metab. Agents Med. Chem. 12, 224–235 (2012).
Saito, T., Yokosuka, T. & Hashimoto-Tane, A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett. 584, 4865–4871 (2010).
Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 family revisited. Annu. Rev. Immunol. 23, 515–548 (2005).
Gonzalez, L. C. et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl Acad. Sci. USA 102, 1116–1121 (2005).
Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nature Immunol. 6, 90–98 (2005).
Brandt, C. S. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495–1503 (2009).
Chattopadhyay, K. et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol. Rev. 229, 356–386 (2009).
Bierer, B. E., Peterson, A., Gorga, J. C., Herrmann, S. H. & Burakoff, S. J. Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor. J. Exp. Med. 168, 1145–1156 (1988).
Cannons, J. L., Tangye, S. G. & Schwartzberg, P. L. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29, 665–705 (2011).
Bengsch, B. et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947 (2010).
Kageyama, R. et al. The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. Immunity 36, 986–1002 (2012).
Zhao, F., Cannons, J. L., Dutta, M., Griffiths, G. M. & Schwartzberg, P. L. Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis. Immunity 36, 1003–1016 (2012).
Schwartzberg, P. L., Mueller, K. L., Qi, H. & Cannons, J. L. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nature Rev. Immunol. 9, 39–46 (2009).
Arnett, H. A., Escobar, S. S. & Viney, J. L. Regulation of costimulation in the era of butyrophilins. Cytokine 46, 370–375 (2009).
Sierro, S., Romero, P. & Speiser, D. E. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin. Ther. Targets 15, 91–101 (2011).
Chan, C. J., Andrews, D. M. & Smyth, M. J. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr. Opin. Immunol. 24, 246–251 (2012).
del Rio, M. L., Lucas, C. L., Buhler, L., Rayat, G. & Rodriguez-Barbosa, J. I. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J. Leukoc. Biol. 87, 223–235 (2010).
Magis, C., van der Sloot, A. M., Serrano, L. & Notredame, C. An improved understanding of TNFL/TNFR interactions using structure-based classifications. Trends Biochem. Sci. 37, 353–363 (2012).
Croft, M. et al. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol. 33, 144–152 (2012).
Sica, G. L. et al. RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-κB. Blood 97, 2702–2707 (2001).
Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
Zhu, Y., Yao, S. & Chen, L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34, 466–478 (2011).
Cai, G. & Freeman, G. J. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 229, 244–258 (2009).
Wang, S. et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96, 2808–2813 (2000).
Lin, D. Y. et al. The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 105, 3011–3016 (2008).
Lazar-Molnar, E. et al. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc. Natl Acad. Sci. USA 105, 10483–10488 (2008).
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007). This paper, along with reference 35, describes a functional interaction between B7-H1 and B7-1.
Park, J. J. et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T cell tolerance. Blood 116, 1291–1298 (2010).
Eissner, G., Kolch, W. & Scheurich, P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15, 353–366 (2004).
Munn, D. H., Sharma, M. D. & Mellor, A. L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100–4110 (2004).
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
Azuma, T. et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635–3643 (2008).
Flies, D. B., Wang, S., Xu, H. & Chen, L. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 187, 1537–1541 (2011).
Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592 (2011).
Boomer, J. S. & Green, J. M. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2, a002436 (2010).
Janardhan, S. V., Praveen, K., Marks, R. & Gajewski, T. F. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS ONE 6, e24931 (2011).
Simpson, T. R., Quezada, S. A. & Allison, J. P. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr. Opin. Immunol. 22, 326–332 (2010).
Rudd, C. E. & Schneider, H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nature Rev. Immunol. 3, 544–556 (2003).
Kroenke, M. A. et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J. Immunol. 188, 3734–3744 (2012).
Choi, Y. S. et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 34, 932–946 (2011).
Rudd, C. E., Taylor, A. & Schneider, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229, 12–26 (2009).
Knieke, K., Lingel, H., Chamaon, K. & Brunner-Weinzierl, M. C. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. PLoS ONE 7, e31391 (2012).
Yokosuka, T. et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209, 1201–1217 (2012).
Yokosuka, T. et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 33, 326–339 (2010).
Sheppard, K. A. et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574, 37–41 (2004).
Patsoukis, N. et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 5, ra46 (2012).
Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L. & Murphy, K. M. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. Biophys. Res. Commun. 312, 1236–1243 (2003).
Gavrieli, M. & Murphy, K. M. Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA. Biochem. Biophys. Res. Commun. 345, 1440–1445 (2006).
Dong, Z. et al. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36, 974–985 (2012).
Cannons, J. L. et al. Biochemical and genetic evidence for a SAP-PKC-θ interaction contributing to IL-4 regulation. J. Immunol. 185, 2819–2827 (2010).
Bloch-Queyrat, C. et al. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J. Exp. Med. 202, 181–192 (2005).
Rangachari, M. et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nature Med. 18, 1394–1400 (2012).
Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nature Rev. Immunol. 9, 271–285 (2009).
Croft, M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature Rev. Immunol. 3, 609–620 (2003).
Wang, C., Lin, G. H., McPherson, A. J. & Watts, T. H. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229, 192–215 (2009).
Nocentini, G. & Riccardi, C. GITR: a modulator of immune response and inflammation. Adv. Exp. Med. Biol. 647, 156–173 (2009).
Xiao, X. et al. OX40 signaling favors the induction of TH9 cells and airway inflammation. Nature Immunol. 13, 981–990 (2012).
Podack, E. R., Strbo, N., Sotosec, V. & Muta, H. CD30-governor of memory T cells? Ann. NY Acad. Sci. 975, 101–113 (2002).
Steinberg, M. W., Cheung, T. C. & Ware, C. F. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244, 169–187 (2011).
Shui, J. W. et al. HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria. Nature 488, 222–225 (2012).
Sakoda, Y. et al. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood 117, 2506–2514 (2011).
Pobezinskaya, Y. L., Choksi, S., Morgan, M. J., Cao, X. & Liu, Z. G. The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling. J. Immunol. 186, 5212–5216 (2011).
Nolte, M. A., van Olffen, R. W., van Gisbergen, K. P. & van Lier, R. A. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229, 216–231 (2009).
Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609–612 (1993). This article showed that CD28 is essential for T cell activation but that in the absence of CD28, other signals can compensate to a limited extent to co-stimulate T cells.
Meinl, E. et al. Differential requirement of ZAP-70 for CD2-mediated activation pathways of mature human T cells. J. Immunol. 165, 3578–3583 (2000).
Green, J. M., Karpitskiy, V., Kimzey, S. L. & Shaw, A. S. Coordinate regulation of T cell activation by CD2 and CD28. J. Immunol. 164, 3591–3595 (2000).
Denoeud, J. & Moser, M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89, 195–203 (2011).
Linterman, M. A. et al. Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. Immunity 30, 228–241 (2009).
Mizui, M. et al. Bimodal regulation of T cell-mediated immune responses by TIM-4. Int. Immunol. 20, 695–708 (2008).
Cao, W., Ryan, M., Buckley, D., O'Connor, R. & Clarkson, M. R. Tim-4 inhibition of T-cell activation and T helper type 17 differentiation requires both the immunoglobulin V and mucin domains and occurs via the mitogen-activated protein kinase pathway. Immunology 133, 179–189 (2011).
Xiao, L. et al. Suppression of allograft rejection by Tim-1-Fc through cross-linking with a novel Tim-1 binding partner on T cells. PLoS ONE 6, e21697 (2011).
Meylan, F., Richard, A. C. & Siegel, R. M. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol. Rev. 244, 188–196 (2011).
Bour-Jordan, H. & Bluestone, J. A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41–66 (2009).
Xiao, X. et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J. Immunol. 188, 892–901 (2012).
Zeiser, R. et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 109, 2225–2233 (2007).
Walker, L. S. & Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nature Rev. Immunol. 11, 852–863 (2011).
Tao, R., Wang, L., Murphy, K. M., Fraser, C. C. & Hancock, W. W. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J. Immunol. 180, 6649–6655 (2008).
Sharma, M. D. et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570–2582 (2007).
Taylor, P. A. et al. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions. J. Immunol. 172, 34–39 (2004).
Paust, S., Lu, L., McCarty, N. & Cantor, H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl Acad. Sci. USA 101, 10398–10403 (2004).
Paterson, A. M. et al. The programmed death-1 ligand 1, B7-1 pathway restrains diabetogenic effector T cells in vivo. J. Immunol. 187, 1097–1105 (2011).
Amarnath, S. et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci. Transl. Med. 3, 111ra120 (2011).
Amarnath, S. et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 8, e1000302 (2010).
Franceschini, D. et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 119, 551–564 (2009).
Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029 (2009).
Baitsch, L. et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE 7, e30852 (2012).
Boesteanu, A. C. & Katsikis, P. D. Memory T cells need CD28 costimulation to remember. Semin. Immunol. 21, 69–77 (2009).
Hendriks, J. et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175, 1665–1676 (2005).
Zhu, Y., Zhu, G., Luo, L., Flies, A. S. & Chen, L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109, 4882–4889 (2007).
Harlin, H., Podack, E., Boothby, M. & Alegre, M. L. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J. Immunol. 169, 2451–2459 (2002).
Redmond, W. L., Ruby, C. E. & Weinberg, A. D. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29, 187–201 (2009).
Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006).
Wherry, E. J. T cell exhaustion. Nature Immunol. 12, 492–499 (2011). This paper provides a detailed review of T cell exhaustion.
Antoine, P. et al. Functional exhaustion of CD4+ T lymphocytes during primary cytomegalovirus infection. J. Immunol. 189, 2665–2672 (2012).
Fourcade, J. et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887–896 (2012).
Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C. & Kuchroo, V. K. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32, 345–349 (2011).
Goldberg, M. V. & Drake, C. G. LAG-3 in cancer immunotherapy. Curr. Top. Microbiol. Immunol. 344, 269–278 (2011).
Wang, C. et al. Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J. Exp. Med. 209, 77–91 (2012). This paper was the first to show that T cell exhaustion can be reversed through co-stimulation.
Schwartz, R. H., Mueller, D. L., Jenkins, M. K. & Quill, H. T-cell clonal anergy. Cold Spring Harb. Symp. Quant. Biol. 54, 605–610 (1989). This was the first paper to use the term anergy to describe the functional unresponsive state induced in T cells in the presence of only TCR stimulation (signal one) in the absence of additional signals (signal two).
McAfee, M. S. & Blattman, J. N. Combating chronic T-cell exhaustion. Immunotherapy 4, 557–560 (2012).
Fife, B. T. & Bluestone, J. A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224, 166–182 (2008).
Takamura, S. et al. Premature terminal exhaustion of friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J. Immunol. 184, 4696–4707 (2010).
Angelosanto, J. M., Blackburn, S. D., Crawford, A. & Wherry, E. J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86, 8161–8170 (2012).
Angelosanto, J. M. & Wherry, E. J. Transcription factor regulation of CD8+ T-cell memory and exhaustion. Immunol. Rev. 236, 167–175 (2010).
Doering, T. A. et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37, 1130–1144 (2012).
Lafferty, K. J. & Cunningham, A. J. A. New analysis of allogeneic interactions. J. Immunol. 112, 436–437 (1975). Lafferty and Cunningham extended the Bretscher and Cohn two-signal model to suggest that T cells require two signals for activation.
Linsley, P. S., Clark, E. A. & Ledbetter, J. A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl Acad. Sci. USA 87, 5031–5035 (1990). This paper identified B7-1 as a ligand for CD28.
Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561–569 (1991). CTLA4 was identified as a second receptor that interacts with B7-1 in this paper.
Azuma, M. et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76–79 (1993). In this paper B7-2 was identified as a second ligand that interacts with both CD28 and CTLA4.
Hathcock, K. S. et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262, 905–907 (1993). This paper and reference 118 identified B7-2 as a second ligand that interacts with CTLA.
Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. & Hodes, R. J. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180, 631–640 (1994).
Inaba, K. et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180, 1849–1860 (1994).
Saito, T. & Yamasaki, S. Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. Immunol. Rev. 192, 143–160 (2003).
Fos, C. et al. ICOS ligation recruits the p50α PI3K regulatory subunit to the immunological synapse. J. Immunol. 181, 1969–1977 (2008).
Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Rev. Immunol. 10, 317–327 (2010).
Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
Linsley, P. S. & Nadler, S. G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev. 229, 307–321 (2009). This review provides an interesting historical perspective of the elucidation of the CD28–B7 pathway, the development of CTLA4Ig, and the progression of CTLA4Ig to US Food and Drug Administration approval as a treatment for rheumatoid arthritis.
Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443–453 (2005).
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252–264 (2012).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y. X. & Melero, I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508–516 (2010).
Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev. Cancer 12, 237–251 (2012).
Curran, K. J., Pegram, H. J. & Brentjens, R. J. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J. Gene Med. 14, 405–415 (2012).
Humphrey, R. W. et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl Cancer Inst. 103, 1222–1226 (2011).